Analysis Valneva’s Future Hinges on Lyme Disease Vaccine Candidate
While Valneva has reviewed its 2025 financial results and confirmed guidance for 2026, the company’s focus remains singularly fixed on an upcoming clinical milestone. The Phase 3 readout for its...